Home › High Blood Pressure › NCT07553442

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Who can join

Ages 18 to 75 · All sexes

Part A: Inclusion Criteria

* Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
* Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications

Part B: Inclusion Criteria

* Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
* Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks

Both Parts: Exclusion Criteria

* Has known secondary hypertension or serum potassium more than 5 mmol/L
* Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2

Note: other protocol defined inclusion / exclusion criteria apply

About the study

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

What is being tested

• ALN-AGT01 RVR (drug)
• Placebo (drug)
• Zilebesiran (drug)

Sponsor: Alnylam Pharmaceuticals · Participants: 93 · Started: Apr 27, 2026

Contact the study team

• Alnylam Clinical Trial Information Line · Phone: 1-877-ALNYLAM
• Alnylam Clinical Trial Information Line · Phone: 1-877-256-9526

Official record on ClinicalTrials.gov — NCT07553442

Locations in the U.S.

Conditions

• High Blood Pressure

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.